Overview


Intellectual Property


Market



Overview


NeuroSolis, Inc. is an early-stage company located in Madison and organized in the State of Wisconsin. We are developing NSX-0527 for neurological and psychiatric indications. Our goal is to help the 5.2 million Americans afflicted with Alzheimer's Disease and the 2.5 million afflicted with schizophrenia. Our drug candidate, NSX-0527, is the culmination of a two-year program to enhance the properties of MCD-386, a compound which had shown positive results in Phase 1 clinical trials. NeuroSolis is currently seeking investment to fund animal safety pharmacology and toxicity studies to enable filing of an Investigational New Drug (IND) application needed to commence human clinical trials.


Intellectual Property


NSX-0527 is protected by United States patent US 8,853,219 B2. This composition-of-matter patent was issued by the USPTO in October of 2014 and offers protection through 2030. Follow-on drug candidate NSX-0559 as well as formulations NSX-0527f and NSX-0559f are covered by Unites States patent applications 13/791,251 and 14/507,609. NeuroSolis intends to apply for additional patents worldwide to cover other formulations currently in development for NSX-0527 and NSX-0559.


Market


The United States is the largest single pharmaceutical market in the world, accounting for about a third of all worldwide sales. For Alzheimer's disease, this totaled nearly $3 billion in 2010. For antipsychotics (used for schizophrenia and other disorders), the highest selling drugs had revenues totaling more than $13 billion in 2010. Treatments for both disorders are currently inadequate and call for novel drugs that provide improved efficacy without an undue side-effect burden. NeuroSolis is pursuing NSX-0527 to meet these needs.